Uses of patient-derived scaffolds
AssigneeIscaff Pharma AB
InventorsGöran Landberg, Anders Ståhlberg
Life of this patent
Estimating the term…
Abstract
Cell-free scaffolds derived from tumors in patients are used as in vitro cancer models and also provide information of the tumor, from which it is derived, including its susceptibility to cancer treatment. The cell-free scaffolds are also used as a predictive tool in assessing cancer treatment efficacy and in identifying immunotargets and biomarkers for cancer therapy.
Claims22
A method of providing an in vitro cancer model, the method comprising:
- selecting (S1) a cell-free scaffold obtained from a tumor in a subject, the tumor having at least one defined tumor property and the cell-free scaffold is selected based on the at least one defined tumor property;
- selecting (S2) cancer cells based on the selected cell-free scaffold, wherein the selected cancer cells are not obtained from the tumor, from which the cell-free scaffold is obtained;
- and
- culturing (S3) the selected cancer cells in the selected cell-free scaffold.
A method of identifying an immunotarget for cancer therapy for a subject, the method comprising:
- culturing (S10) cancer cells in a cell-free scaffold obtained from a tumor in the subject;
- analyzing (S11) expressions of immunomarkers in the cancer cells;
- and
- selecting (S12) at least one immunomarker as an immunotarget for cancer therapy for the subject based on the expressions of immunomarkers in the cancer cells.
14-21. (canceled)
A method of determining at least one tumor property of a tumor in a subject, the method comprising:
- culturing (S30) cancer cells, preferably breast cancer cells, in a cell-free scaffold obtained from a tumor in the subject;
- analyzing (S31) the expression of at least one immunomarker selected from the group consisting of programmed death ligand 1 (PDL1), colony stimulating factor 1 (CSF1) and chemokine C—C motif ligand 2 (CCL2) in the cancer cells;
- and
- determining (S32) the at least one tumor property based on the expression of the at least one immunomarker.
23-45. (canceled)
Dependencies are inferred from the claim text.